Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap5.09B
Enterprise Value5.11B
Trailing P/E227.36
APLS
(NASDAQ)Apellis Pharmaceuticals, Inc.
$40.41-- (--)
Loading... - Market loading
Apellis Pharmaceuticals (APLS) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)5.07
Forward Price/Sales3.95
Price/Book (mrq)13.75
Price/Tangible Book (mrq)13.75
Price/OCF (ttm)112.30
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue5.09
EV/Earnings228.19
EV/EBITDA72.99
EV/EBIT55.71
Stock Price
Current price, 52-week range, and moving averages
Current Price$40.41
1-Day Change0.40%
52-Week High$40.45
52-Week Low$16.10
52-Week Change78.09%
YTD Change56.19%
1-Year Change75.61%
50-Day MA$21.49
200-Day MA$22.64
Avg Volume (30 day)10.33M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding126.02M
Book Value per Share$2.94
Net Cash per Share$2.91
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$37.33
Target Upside/Downside-7.62%
Analyst ConsensusHold
Analyst Count24
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin89.81%
EBITDA Margin (ttm)6.97%
EBIT Margin (ttm)9.13%
Operating Margin (ttm)5.52%
Pretax Margin (ttm)2.40%
Profit Margin (ttm)2.23%
FCF Margin (ttm)7.74%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)6.05%
Return on Assets (ttm)2.08%
Return on Invested Capital (ttm)21.91%
Return on Capital Employed (ttm)12.20%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue1.00B
Gross Profit901.55M
Operating Income55.43M
Pretax Income24.11M
Net Income22.39M
EBITDA70.00M
EBIT91.69M
Diluted EPS$0.18
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow45.33M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth28.46%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)1.08B
Cash & Securities (mrq)467.76M
Net Cash (mrq)367.01M
Net Cash per Share$2.91
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)486.31M
Working Capital (mrq)691.24M
Total Equity (mrq)370.15M
Book Value per Share$2.94
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)3.14
Quick Ratio (mrq)2.70
Debt/Equity (mrq)1.31
Debt/EBITDA (ttm)6.95
Debt/FCF (ttm)5.78
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield0.44%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score2.39
Piotroski F-Score7/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$3.43
Graham Upside/Downside-91.52%
Frequently Asked Questions About Apellis Pharmaceuticals Statistics
What are the key financial metrics for APLS?
Apellis Pharmaceuticals, Inc. (APLS) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is APLS's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Apellis Pharmaceuticals is overvalued or undervalued.
How do I read APLS's profitability ratios?
Apellis Pharmaceuticals's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do APLS's debt ratios indicate?
The financial health section shows Apellis Pharmaceuticals's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is APLS's dividend analysis?
The dividend section covers Apellis Pharmaceuticals's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.